Kalaris Therapeutics (NASDAQ:KLRS) Director Buys $5,000,005.74 in Stock

Kalaris Therapeutics Inc. (NASDAQ:KLRS) Director Srinivas Akkaraju bought 479,847 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was purchased at an average cost of $10.42 per share, for a total transaction of $5,000,005.74. Following the completion of the transaction, the director directly owned 1,979,847 shares of the company’s stock, valued at approximately $20,630,005.74. The trade was a 31.99% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kalaris Therapeutics Trading Up 7.2%

KLRS opened at $10.98 on Friday. The company’s 50 day moving average is $9.20 and its 200 day moving average is $6.33. The company has a market cap of $205.33 million, a price-to-earnings ratio of -2.91 and a beta of -0.09. Kalaris Therapeutics Inc. has a 12-month low of $2.14 and a 12-month high of $12.90.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KLRS. Chardan Capital initiated coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 target price on the stock. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Citizens Jmp assumed coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen downgraded shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.00.

Hedge Funds Weigh In On Kalaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics in the second quarter valued at $65,000. Fortis Capital Advisors LLC bought a new position in Kalaris Therapeutics during the third quarter valued at $231,000. Belpointe Asset Management LLC purchased a new position in shares of Kalaris Therapeutics in the 3rd quarter worth $231,000. Johnson Financial Group Inc. bought a new stake in shares of Kalaris Therapeutics in the 3rd quarter worth about $58,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Kalaris Therapeutics in the 3rd quarter worth about $130,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.